Lantern Pharma Inc. filed a Form 8-K with the SEC on September 24, 2026, disclosing that the company hosted a live webinar on September 23, 2026, to discuss its Open-Medicine AI multi-agentic AI platform for drug development.
Key Highlights
- Webinar date: Lantern Pharma hosted the live webinar on September 23, 2026.
- Topic disclosed: The webinar focused on the Open-Medicine AI multi-agentic AI platform for drug development.
- Exhibit furnished: A copy of the presentation used during the webinar was furnished as Exhibit 99.1 to the filing.
- Regulation FD: The disclosure was made under Item 7.01, Regulation FD Disclosure.
- Filing signed by: David R. Margrave, Chief Financial Officer, signed the report on September 23, 2026.
Lantern Pharma Shares Details on Its AI-Driven Drug Development Platform
According to the filing, Lantern Pharma Inc. (NASDAQ:LTRN), a Delaware corporation headquartered at 1920 McKinney Avenue, 7th Floor, Dallas, Texas 75201, held a live webinar on September 23, 2026, centered on its Open-Medicine AI platform. The company described the platform as a multi-agentic AI system intended to assist with drug development activities. The filing furnished the accompanying presentation as Exhibit 99.1, which the company stated was used to support discussions during the webinar.
The filing noted that the information disclosed under Item 7.01, including Exhibit 99.1, "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, as amended," and is not subject to the liabilities of that section. The company further stated that the materials are not to be deemed incorporated by reference in any filings under the Securities Act of 1933 or the Exchange Act unless expressly incorporated by specific reference. A replay of the webinar and the investor presentation were indicated as available for the public.
What Was Disclosed
Lantern Pharma's Form 8-K reported a September 23, 2026, webinar covering its Open-Medicine AI multi-agentic drug development platform. The accompanying presentation was furnished as Exhibit 99.1 and the disclosure was made under Regulation FD.



Please wait processing your request...